文献速递生殖医学

胚胎移植前使用Essure®治疗输卵管积水的女性流产率较高:系统综述与Meta分析

High miscarriage rate in women treated with Essure® for hydrosalpinx before embryo transfer: a systematic review and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2016-01-01

该系统综述与Meta分析检索截至2015年11月7日的数据库,纳入26项研究43个研究组,评估Essure®与其他干预或无干预在胚胎移植前治疗输卵管积水的效果与安全性。与无干预相比,Essure®组每次胚胎移植的临床妊娠率更高(36% vs 13%),但与其他干预相比,Essure®组每次临床妊娠的流产率更高(38% vs 15%)。作者认为输卵管切除术应作为适合腹腔镜女性的首选,但对不适合手术者尚需随机对照试验。

要点

  • 与无干预相比,Essure®组每次胚胎移植临床妊娠率36% vs 13%。
  • 与其他干预相比,Essure®组每次临床妊娠流产率38% vs 15%。
  • 作者认为适合腹腔镜的女性应首选输卵管切除术。

核心结论

  • 现有证据提示,胚胎移植前使用Essure®治疗输卵管积水虽较无干预提高临床妊娠机会,但与其他干预相比流产率更高。
  • 作者认为,尽管证据基于观察性研究,对适合腹腔镜的女性,输卵管切除术应作为首选。
  • 作者认为,对不适合手术的女性,目前做出推荐仍为时过早,需要随机对照试验明确最佳治疗选择。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Scopus、CENTRAL、Web of Science和ClinicalTrials.gov及合格研究的参考文献列表。
  • 电子数据库检索于2015年11月7日进行。
  • 纳入至少10例输卵管积水女性在胚胎移植前接受Essure®、其他干预或无治疗的研究,共26项研究43个研究组。
  • 研究组包括:评估Essure® 8个、输卵管抽吸7个、无治疗7个、输卵管切除术12个、输卵管离断2个、输卵管阻塞7个。
  • 研究选择、数据提取和偏倚风险评估由两名作者独立完成,采用随机效应模型汇总各结局和干预的比例及95%CI。

主要发现

  • 与无干预相比,Essure®组每次胚胎移植的临床妊娠率为36%(95%CI 0-43%),无干预组为13%(95%CI 9-17%)。
  • 与其他干预相比,Essure®组每次临床妊娠的流产率为38%(95%CI 27-49%),其他干预组为15%(95%CI 10-19%)。

关键数值与推荐

  • 结局指标包括每次临床妊娠的流产、每次单胎活产的单胎早产、每次胚胎移植的活产/持续妊娠和临床妊娠。
  • 各结局和干预的汇总结果以比例及95%CI表示,采用随机效应模型。

临床怎么用

  • 作者认为,对适合腹腔镜的女性,输卵管切除术应作为首选。
  • 作者认为,对不适合手术的女性,目前做出推荐仍为时过早,需要随机对照试验明确最佳治疗选择。

局限性

  • 证据基于观察性研究。
  • 作者认为对不适合手术的女性做出推荐仍为时过早,需要随机对照试验明确最佳治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Essure® has been tested as an alternative treatment for hydrosalpinx before embryo transfer (ET) in women undergoing assisted reproduction techniques. However, the persistence of a foreign body inside the uterine cavity might have a negative impact on the outcome of pregnancy. The present systematic review aimed at identifying, appraising and summarizing the available evidence regarding the effectiveness and safety of using Essure prior to ET for women with hydrosalpinx. METHODS: We searched for studies in PubMed, Scopus, CENTRAL, Web of Science and ClinicalTrials.gov and the reference lists of eligible studies. All studies including at least 10 women with hydrosalpinx who received Essure, any other intervention or no treatment prior to ET were considered eligible. Study selection, data extraction and evaluation of the risk of bias were performed independently by two authors. Study outcomes were miscarriage per clinical pregnancy, singleton preterm birth per singleton live birth and live birth/ongoing pregnancy and clinical pregnancy per ET. The pooled results for each outcome and intervention were summarized as proportions with their respective 95% CIs, using a random-effects model. RESULTS: Our electronic search of databases was performed on 7 November 2015, and 26 studies with 43 study arms were considered eligible: eight study arms evaluating Essure; seven assessing tubal aspiration; seven appraising effects of no treatment; 12 evaluating salpingectomy; two assessing tubal division; and seven evaluating tubal occlusion. When compared with women who had no intervention, women with Essure had a higher clinical pregnancy rate per ET (36% (95% CI, 0-43%) vs 13% (95% CI, 9-17%)). When compared with women who had other interventions, women with Essure had a higher miscarriage rate per clinical pregnancy (38% (95% CI, 27-49%) vs 15% (95% CI, 10-19%)). CONCLUSIONS: The available evidence suggests that, although Essure prior to ET in women with hydrosalpinx improves the chance of achieving a clinical pregnancy compared with no intervention, it is associated with a higher rate of miscarriage when compared with the other interventions. Although this evidence is based on observational studies, we believe that salpingectomy should be the first option for women who are eligible for videolaparoscopy. However, it is still premature to make recommendations for women who are not eligible for surgery, and randomized controlled trials are needed to clarify which is the best treatment alternative in such a scenario. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Barbosa MW, Sotiriadis A, Papatheodorou SI, et al. High miscarriage rate in women treated with Essure® for hydrosalpinx before embryo transfer: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2016. PMID: 27854386. doi:10.1002/uog.15960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。